Seminar Briefing
Seminar Briefings are concise summaries of the presentations and discussions at seminars and conferences organised by OHE.
How do we Measure the “Value” in Value-Based care?
1 October 2020
Determining and defining value in health care is a persistent challenge in every country. To some extent, what constitutes value depends on perspective, e.g. a pharmaceutical company…
Incentives for R&D: Payment Options and Pricing Challenges
8 January 2020
The issue of rising prescription drug prices is a concern in every country. Dozens of policy initiatives and hundreds of research projects over last the fifty…
Personalised Medicine: is it an Oil-Rush or Oil-Spill?
1 May 2020
Personalised medicine, also known as ‘precision’ or ‘stratified’ medicine, targets treatment by using genetics and/or biomarkers to identify patients or subgroups of patients who have distinct…
Closing the ‘Know-Do’ Gap for Health Systems Reform at the Policy Level
1 April 2020
The World Health Organisation (WHO) has become quite skilled at promoting what changes are desirable in health care systems, and why, but has largely left how…
What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment
2 January 2020
The NHS Improvement Economics team is part of the Strategy Directorate in NHS Improvement. NHS Improvement aims to implement changes to help improve both quality and…
Evaluating the Cost-effectiveness of Health System Strengthening: A Platforms Perspective
1 February 2020
Health System Strengthening (HSS) is an important concept now widely discussed, but too often without sufficient structure or an adequate understanding of what actually is involved. The articles on which this seminar is based (Morton, Thomas and Smith, 2016; Smith and Yip, 2016) attempted to present more clearly just what health system strengthening might entail and whether that might be modelled.
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
1 February 2019
Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available…
Securing Funds for the Proposed NHS Multi-year Funding: The Feasibility of Using a Hypothecated Tax
1 October 2018
This OHE publication by Nick Timmins, a senior fellow at the Institute for Government and the Kings Fund, sets out arguments in favour and against. It…
The UK Biotech Sector and Brexit: Past Performance and Future Prospects
1 April 2018
This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2)…